Artificial Intelligence in Mammography Screening in Norway

Breast Cancer Clinical Trial

— AIMS Norway  

Official title:

Artificial Intelligence in BreastScreen Norway - a Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06032390
• Other study ID #: 366405
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 2024
• Est. completion date: June 2033

Study information

• Verified date: June 2023
• Source: Cancer Registry of Norway
• Contact: Solveig Hofvind, PhD
• Phone: 22928828
• Email: sshh[@]kreftregisteret.no
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this randomized controlled trial is to compare the number of breast cancers detected among women who had their screening mammograms interpreted by artificial intelligence (AI) in combination with one or two breast radiologists to the number of breast cancers detected after standard independent double reading in BreastScreen Norway. The aims of the study is to prove that screening interpretation with AI in combination with one or two radiologists (the intervention) is non-inferior to standard interpretation procedure.

Description:

Independent double reading with consensus is the recommended practice for breast cancer screening programs in Europe. This is a time-consuming process and more than 99% of examinations are determined to have a negative final outcome in BreastScreen Norway. However, radiologist still overlook cancers, and review-studies have shown 20-25% of screen-detected and interval cancers to be visible at prior screening mammograms. In Norway and other countries, there is also a shortage of breast radiologists. Retrospective studies on AI in mammographic screening have shown promising results in the classification of cancer negative and cancer positive examinations. However, prospective studies are needed to elucidate questions concerning AI as a support or replacement for the radiologists in the interpretation process. In this randomized controlled trial women attending screening and consenting to participate in the study, will be randomized (1:1 allocation) to an intervention or a control group. The screening examination will be performed as usual in both groups. The intervention in the trial is the interpretation procedure. All examinations will be analyzed by AI. In the intervention group, examinations will be triaged according to risk of malignancy defined by an AI score. Examinations with a low AI score will have a single reading by one radiologist and examinations with a intermediate or high AI score will have an independent double reading by two radiologists. All examinations selected by either one or both radiologist will be discussed at consensus. Examinations with an AI raw score of 9.8 or above will be discussed at consensus independent of the radiologists' interpretation. The radiologists will be blinded to whether the mammograms are interpreted by one or two radiologists. AI risk scores and AI image marking of suspicious calcifications and masses are only provided to the radiologists at consensus, not during independent reading. In the control group, two independent radiologists will interpret all screening examinations according to standard procedure, independent double reading. AI results will not be available at either independent reading or consensus, only for comparison with the intervention group in final analyses. Screen-detected cancers in the intervention and control arm will be analyzed in terms of non-inferiority.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 150000
• Est. completion date: June 2033
• Est. primary completion date: December 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 50 Years to 69 Years

Eligibility

Inclusion Criteria:

• Women attending the population-based mammography screening program BreastScreen Norway providing a signed, informed consent

Exclusion Criteria:

• Women attending the population-based mammography screening program BreastScreen Norway not providing a signed, informed consent, or with breast implants

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Other:
• AI assisted mammography screening interpretation
Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in consensus. Examinations with an AI score of 9.8 and above will be selected to consensus by default. Risk scores and AI image markings are provided to the readers only in consensus. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
• Standard mammography screening interpretation
Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in consensus, and the readers will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.

Locations

Country	Name	City	State
n/a

Sponsors (5)

Lead Sponsor	Collaborator
Cancer Registry of Norway	Helse Midt-Norge, Helse Nord, Helse Vest, Norwegian Cancer Society

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Screen-detected breast cancers	Number of breast cancers detected at screening per 1000 screening examinations.	36 months from study start-up
Secondary	Consensus rate	Proportion of participant discussed in consensus among all participants (%).	24 months from study start-up
Secondary	Recall rate	Proportion of women recalled for further assessment among all participants (%).	24 months from study start-up
Secondary	Interval breast cancers	Number of interval breast cancers diagnosed per 1000 screening examinations.	60 months from study start-up
Secondary	Prognostic and predictive tumor characteristics of screen-detected breast cancer	Distribution of tumor characteristics among the participants with screen-detected breast cancer.	36 months from study start-up
Secondary	Prognostic and predictive tumor characteristics of interval breast cancer	Distribution of tumor characteristics among the participants with interval breast cancer.	60 months from study start-up
Secondary	Sensitivity	Proportion of true positives among true positive and false negatives (%).	60 months from study start-up
Secondary	Specificity	Proportion of true negatives among true negatives and false positives (%).	60 months from study start-up
Secondary	Mammographic features of screen-detected breast cancer	Distribution of characteristics of tumors observed on the mammograms of participants diagnosed with screen-detected breast cancer.	36 months from study start-up
Secondary	Time spent screen-reading	Time (minutes:seconds) spent by the individual radiologists interpreting screening mammograms	36 months from study start-up